SCOTTSDALE, Ariz., Feb. 27, 2020 /PRNewswire/ -- Axon (Nasdaq:
AAXN), the global leader in connected public safety technologies,
today released the following quarterly update letter to
shareholders.
Dear Shareholders,
We are pleased to report a strong finish to 2019.
Revenue grew 26% to $531 million
for the year, driven by demand for our latest generation camera,
Axon Body 3, the cloud-connected TASER 7, and our cloud
software.
Bottom line performance reflects our ability to scale
manufacturing of TASER 7, continued growth of higher margin Axon
Cloud revenue (up 41% for the full year), and cost control
discipline. While net income was affected by catch-up stock
compensation expense, we delivered a record $88 million in adjusted EBITDA for the full year,
up 43%, and Q4 2019 adjusted EBITDA more than tripled to
$38 million, reflecting a 22%
margin.
The successful launch of Axon Body 3 drove record Q4 2019 sales
of $172 million, up 50%, and holds
tremendous strategic value. Customers are enthusiastic about better
core performance and situational awareness features such as
live-video streaming and real-time alerts. With LTE connectivity,
GPS and a more powerful CPU for edge-AI processing, Axon Body 3 is
designed to improve officer performance and drive adoption of SaaS
features. Importantly, this is expected to fuel continued growth in
annual recurring SaaS revenue. Axon Body 3's communications
capabilities also pave the way for adoption of the emergency
dispatch solution we are bringing to market this year.
Our strategic focus on driving recurring cash flow and building
a self-reinforcing SaaS-centric business is working. For example,
in 2019:
- We achieved $161 million in
annual recurring SaaS revenue, up 49% over 2018;
- 71% of our full-year revenue was in recurring contracts, up
from 55% in 2018 and 46% in 2017;
- More than 100 agencies adopted Officer Safety Plan 7, which
carries per-officer-per-month pricing of $149 to $229 and
created a pipeline of customers that have gained access to Axon
Records;
- More than 70% of Officer Safety Plan 7 users are on the
top-tier 7+ plan; and
- More than 550 agencies adopted the cloud-connected TASER 7,
with 80% of those selecting our highest value plans.
We continue to see customer enthusiasm for Axon Records, which
underscores the effectiveness of our go-to-market strategy. We've
made it attractive for agencies to start using Records by including
it as a built-in benefit to our highest tier Officer Safety Plan —
and some agencies will be able to fund the majority of their
upgrade to that tier with savings from transitioning their legacy
records management system to Axon Records.
Our strategic priorities in 2020 include continuing to execute
in our core market, while accelerating our path-to-market in new
product categories such as de-escalation and communications, and
expanding to new customer categories. This will position us to
achieve a higher level of annual recurring SaaS revenue over the
long term. Specifically:
- We are accelerating our R&D investments in developing
real-time command-and-control software for public safety, which
represents a $2 billion rapidly
growing market. Axon's cloud-based software will be designed to
empower everyone involved in incident response: dispatchers, call
takers, command staff, patrol officers, firefighters and medical
personnel. We intend to fundamentally improve the workflow that the
industry refers to as Computer Aided Dispatch, or CAD — enabling
entire agencies to respond as one team to get the right people with
the right information to the right place at the right time. We
expect to be live by mid-year with our first paying customer.
- We see a major opportunity in the corrections and federal law
enforcement channels. In Q4 2019, Axon won a Department of Justice
contract to equip Bureau of Alcohol, Tobacco, Firearms and
Explosives officers with body cameras. This contract vehicle will
also allow other federal law enforcement agencies to join the Axon
network. We are now proud to support both the US Forest Service's
adoption of body cameras and TASER devices, and the DOJ's new body
camera pilot effort, both representing significant milestones in
Axon's federal expansion efforts. We estimate these two markets add
$1.5 billion to our core municipal
public safety market.
Unlocking new opportunities means Axon's strategic growth areas
have evolved and expanded into:
- De-escalation: Developing tools that support public safety
officers in avoiding or minimizing use of force is a key component
of Axon's mission to protect life. These tools include the
cloud-connected TASER conducted energy device as well as a suite of
Augmented Reality and Virtual Reality (AR/VR) training services for
law enforcement, delivered through our Axon Academy training
platform. To obsolete the bullet, we intend to not only develop
more effective TASER devices over time but also drive training and
adoption of the best practices in modern policing.
- Sensors: Our digital evidence management software, Axon
Evidence, supports our network of cloud-connected cameras and
sensors. Axon Evidence is the world's largest cloud-hosted data
repository of law enforcement video data and other types of
electronic evidence. In September
2019, we began shipping Axon Body 3, a camera with an LTE
antenna and GPS chip, which supports real-time awareness.
- Productivity: Our productivity suite of tools reduce time spent
on paperwork. Axon Records takes a disruptive modern approach to
displace legacy on-premises Records Management Systems (RMS) by
putting body camera video at the heart of incident records. Axon
Records includes Axon Standards, a radically simpler approach to
use-of-force reporting. Another software solution in this suite,
Axon Performance, helps agencies ensure that officers are adhering
to agency policies, and provides analytics on the effectiveness of
body-worn camera programs. And Redaction Assistant enables agencies
to redact videos in a fraction of the time through the use of
artificial intelligence (AI).
- Communications: We are developing communication tools that
support real-time situational awareness through the sharing of
information across various channels, including voice, messaging,
location mapping, and intelligence and evidence sharing. Products
include Axon Aware, which allows agencies to know the GPS location
of their officers and what those officers are experiencing through
live video streaming and more; and Axon Dispatch, the emergency
dispatch solution we are bringing to market this year.
By 2030, we believe:
- TASER devices will be the primary means to stop a threat
- AI-enabled body cameras will eliminate the majority of manual
report writing
- Cloud-enabled devices will be the primary means to dispatch
officers in the field
- Axon will be a household name by virtue of the transformative
value we'll create for society and all of our stakeholders
Summary of Q4 2019 results:
- Record quarterly revenue of $172
million, up 50% year over year, included $26 million of Axon Body 3 hardware shipments,
and reflected a successful product launch.
- Total company gross margin of 53.9% reflected a
higher-than-usual mix of body camera hardware and TASER 7
cartridges, as expected. For more details, please see gross margin
commentary by segment, below.
- Operating expenses of $107
million included $47.5 million
in stock-based compensation expenses, including $33 million of incremental "catch up" expense.
Operating expenses excluding stock-based compensation declined
sequentially, reflecting rigorous cost controls.
-
- SG&A of $78 million included
$40.2 million in stock-based
compensation expenses, including $29.9
million in "catch up" expenses.
- R&D of $29 million included
$7.3 million in stock-based
compensation expenses, including $2.9
million in "catch up" expenses.
- These "catch up" expenses are tied to Axon's CEO Performance
Award and eXponential Stock Performance Plan ("XSPP"), for which
six additional performance goals became probable of attainment
during Q4 2019 due to our strengthened outlook, bringing the total
number of performance goals that are statistically probable to
nine.
- GAAP EPS was ($0.21); Non-GAAP
EPS of $0.41 excludes non-cash
stock-based compensation expense.
-
- GAAP EPS includes the "catch-up" stock-based compensation
expense referred to above.
- For more details about Axon's innovative stock-based
compensation plans, which were approved by shareholders and align
the interests of management and employees with shareholders, please
see our online FAQ.
- Quarterly Adjusted EBITDA was a record $38 million, representing 22% margin on revenue,
and 48% incremental contribution margin. For the full year,
adjusted EBITDA grew 43% to $88
million.
- Cash and investments grew $43
million sequentially to approximately $396 million. Axon's strong balance sheet, with
zero debt, provides us with the latitude to continue growing our
subscription contracts as a percentage of revenue.
Financial commentary by segment:
TASER:
|
THREE MONTHS
ENDED
|
|
CHANGE
|
|
|
|
|
|
31 DEC
2019
|
|
30 SEP
2019
|
|
31 DEC
2018
|
|
QoQ
|
|
YoY
|
|
(in
thousands)
|
|
|
|
|
Net sales
|
$
|
83,955
|
|
|
$
|
71,743
|
|
|
$
|
65,301
|
|
|
17.0
|
%
|
|
28.6
|
%
|
Gross
margin
|
60.5
|
%
|
|
63.1
|
%
|
|
65.0
|
%
|
|
-260bp
|
|
-450bp
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
- TASER revenue of $84 million grew
29% year over year, reflecting strong momentum in TASER 7, which
began shipping in Q4 2018, and strong cartridge shipments in the
quarter, reflecting our ability to meet a substantial demand
backlog.
- TASER gross margin declined, as expected, due to the mix of
TASER 7 cartridges shipped in the quarter. We anticipate that
segment gross margin will improve in 2020, building throughout the
year, driven by product mix, continued TASER 7 program cost
optimization and a reduction in discounts.
Software & Sensors:
|
THREE MONTHS
ENDED
|
|
CHANGE
|
|
|
|
|
|
31 DEC
2019
|
|
30 SEP
2019
|
|
31 DEC
2018
|
|
QoQ
|
|
YoY
|
|
(in
thousands)
|
|
|
|
|
Axon Cloud net
sales
|
$
|
36,805
|
|
|
$
|
34,021
|
|
|
$
|
25,774
|
|
|
8.2
|
%
|
|
42.8
|
%
|
Axon Cloud gross
margin
|
76.1
|
%
|
|
75.8
|
%
|
|
74.5
|
%
|
|
30bp
|
|
160bp
|
|
|
|
|
|
|
|
|
|
|
Sensors and Other net
sales
|
$
|
51,091
|
|
|
$
|
25,073
|
|
|
$
|
23,716
|
|
|
103.8
|
%
|
|
115.4
|
%
|
Sensors and Other
gross margin
|
27.0
|
%
|
|
36.4
|
%
|
|
15.7
|
%
|
|
-940bp
|
|
1,130bp
|
- Axon Cloud revenue grew 43% and achieved gross margins of 76.1%
in Q4 2019. This margin includes some low-to-no-margin professional
services that support new installations for SaaS customers. The
software-only revenue in this segment, which includes cloud storage
and compute costs, has consistently carried a gross margin above
80%.
- Strong revenue in the Sensors and Other category was driven by
record body camera shipments of about 83,000 units, topping the
previous record of nearly 29,000 units shipped in Q3 2017. (These
unit figures exclude the Axon Flex line-of-sight camera, which
affixes to an officer's sunglasses or hat brim.) Approximately 75%
of Q4 2019 body camera unit shipments were Axon Body 3. We expect a
significantly lower run-rate of body camera unit sales going
forward.
- Sensors and Other gross margin of 27% was in line with our
expectations. As a reminder, we manage toward a 25% gross margin
for camera and sensors hardware, and the gross margin will
fluctuate quarter to quarter depending on the customer mix.
Forward-Looking Performance Indicators:
|
31 DEC
2019
|
|
30 SEP
2019
|
|
30 JUN
2019
|
|
31 MAR
2019
|
|
31 DEC
2018
|
|
($ in
thousands)
|
Annual recurring
revenue (1)
|
$
|
161,277
|
|
|
$
|
141,540
|
|
|
$
|
129,452
|
|
|
$
|
122,276
|
|
|
$
|
108,496
|
|
Total company future
contracted revenue
|
$
|
1,230,000
|
|
|
$
|
1,130,000
|
|
|
$
|
1,050,000
|
|
|
$
|
930,000
|
|
|
$
|
900,000
|
|
Percentage of TASER
devices sold on a recurring payment plan
|
58
|
%
|
|
55
|
%
|
|
60
|
%
|
|
42
|
%
|
|
35
|
%
|
(1) Monthly recurring license, integration,
warranty, and storage revenue annualized.
- Annual recurring revenue grew 49% year over year to
$161 million, driven by strong
adoption of our integrated software-heavy bundles and
features.
- Total company future contracted revenue grew to $1.23 billion. This amount is limited to revenue
from arrangements that meet the definition of a contract under
Topic 606 as of December 31, 2019. We
expect to recognize between 20% to 25% of this balance over the
next 12 months and generally expect the remainder to be recognized
over the following five to seven years, subject to risks related to
delayed deployments, budget appropriation or other contract
cancellation clauses.
- We have substantially moved the needle on driving TASER
subscriptions in the past year. Approximately 58% of all devices
sold in Q4 were on a recurring payment plan, compared with 35% a
year ago. In the United States,
recurring payment plans accounted for 65% of new TASER contracts,
with TASER 7 contracts driving subscriptions. This represents
significant progress toward transitioning the TASER business to a
subscription model.
- Record quarterly software and sensors bookings of $171 million were up 55% year over year. Going
forward, we will not be disclosing this metric. It was introduced
in the early days of our Software & Sensors business, and is no
longer strategically relevant to evaluating the health of the
segment. We believe that total company future contracted revenue is
a more relevant and comprehensive forward-looking performance
indicator, as it encompasses all company contracts, including
TASER.
- We ended the year with 465,200 users on the Axon network. Going
forward, we are retiring this metric, which is declining in
relevance as our business continues to evolve. We believe that
annual recurring revenue provides a more useful measure of the
health of the SaaS business we are building.
Outlook:
For the full year 2020, we expect to achieve:
- Revenue in the range of $615
million to $625 million;
-
- At the midpoint, this represents 17% year-over-year growth, and
more than 20% year-over-year growth excluding the surge of Axon
Body 3 hardware shipments in Q4 2019;
- We anticipate that Q1 2020 revenue will increase approximately
13% year-over-year;
- We anticipate that 2020 revenue will accelerate in the second
half of the year, with a back-half weighting similar to 2019;
- Adjusted EBITDA in the range of $100
million to $105 million;
-
- Adjusted EBITDA guidance reflects modest gross margin
improvement over 2019, which will be partially offset by camera
hardware shipments to major city customers;
- Adjusted EBITDA guidance reflects accelerated investments to
take advantage of total addressable market expansion opportunities
in new product categories, such as communications, and new customer
categories, such as federal and corrections, as described above,
and in building out systems for scale;
- Adjusted EBITDA guidance excludes expected legal costs of up to
$15 million associated with
litigation involving the FTC, which we intend to treat as an
add-back to Adjusted EBITDA;
- We expect Adjusted EBITDA margin of approximately 10% to 12% in
Q1 2020;
- We expect a normalized tax rate of 20% to 25%, which can
fluctuate depending on geography of income and the effects of
discrete items, including changes in our stock price;
- We expect stock-based compensation expenses to be approximately
$85 million for the full year, which
is subject to change depending on our assessment of the probability
of attaining operational metrics for the CEO Performance Award and
XSPP awards, and the expected timing of such attainment; and
- We are closely monitoring our supply chain and operations in
the context of the coronavirus crisis. Though the situation is
dynamic, at this time, we believe the potential impact to Axon is
reflected in our full-year guidance.
This is an exciting time for Axon and its customers -- the
products we are bringing to market are fundamentally improving
public safety, creating massive societal value, and saving lives.
Thank you for joining us on this journey.
Signed,
Rick Smith, CEO
Luke Larson, President
Jawad Ahsan, CFO
Quarterly conference call and Webcast
We will host our Q4 2019 earnings conference call on
February 27 at 2 p.m. PT / 5 p.m.
ET.
The call will be available via live audio webcast and archived
replay on Axon's investor relations website at
https://investor.axon.com.
Statistical Definitions
Software and Sensors bookings are an indication of the activity
the Company is seeing relative to Software and Sensors hardware,
software and Axon Evidence. We consider bookings to be a
statistical measure defined as the sales price of orders (not
invoiced sales), including contractual optional periods we expect
to be exercised, net of cancellations, inclusive of renewals,
placed in the relevant fiscal period, regardless of when the
products or services ultimately will be provided. Most bookings
will be invoiced in subsequent periods.
Due to municipal government funding rules, in some cases certain
of the future period amounts included in bookings are subject to
budget appropriation or other contract cancellation clauses.
Although Axon has entered into contracts for the delivery of
products and services in the future and anticipates the contracts
will be fulfilled, if agencies do not exercise contractual options,
do not appropriate money in future year budgets or do enact a
cancellation clause, revenue associated with these bookings may not
ultimately be recognized, resulting in a future reduction to
bookings.
For more information relative to our revenue recognition
policies, please reference our SEC filings.
Non-GAAP Measures
To supplement the Company's financial results presented in
accordance with GAAP, we present the non-GAAP financial measures of
EBITDA, Adjusted EBITDA, Non-GAAP Net Income, Non-GAAP Diluted
Earnings Per Share and Free Cash Flow. The Company's management
uses these non-GAAP financial measures in evaluating the Company's
performance in comparison to prior periods. We believe that both
management and investors benefit from referring to these non-GAAP
financial measures in assessing its performance, and when planning
and forecasting our future periods. A reconciliation of GAAP to the
non-GAAP financial measures is presented herein.
- EBITDA (Most comparable GAAP Measure: Net income) - Earnings
before interest expense, investment interest income, income taxes,
depreciation and amortization.
- Adjusted EBITDA (Most comparable GAAP Measure: Net income) -
Earnings before interest expense, investment interest income,
income taxes, depreciation, amortization, non-cash stock-based
compensation expense and pre-tax certain other items (described
below).
- Non-GAAP Net Income (Most comparable GAAP Measure: Net income)
- Net income excluding the costs of non-cash stock-based
compensation and excluding pre-tax certain other items, including,
but not limited to, net gain/loss/write-down/disposal/abandonment
of property, equipment and intangible assets; loss on impairment;
and costs related to business acquisitions. The Company tax-effects
non-GAAP adjustments using the blended statutory federal and state
tax rates for each period presented.
- Non-GAAP Diluted Earnings Per Share (Most comparable GAAP
Measure: Earnings Per share) - Measure of Company's Non-GAAP Net
Income divided by the weighted average number of diluted common
shares outstanding during the period presented.
- Free Cash Flow (Most comparable GAAP Measure: Cash flow from
operating activities) - cash flows provided by operating activities
minus purchases of property and equipment, intangible assets and
cash flows related to business acquisitions.
Caution on Use of Non-GAAP Measures
Although these non-GAAP financial measures are not consistent
with GAAP, management believes investors will benefit by referring
to these non-GAAP financial measures when assessing the Company's
operating results, as well as when forecasting and analyzing future
periods. However, management recognizes that:
- these non-GAAP financial measures are limited in their
usefulness and should be considered only as a supplement to the
Company's GAAP financial measures;
- these non-GAAP financial measures should not be considered in
isolation from, or as a substitute for, the Company's GAAP
financial measures;
- these non-GAAP financial measures should not be considered to
be superior to the Company's GAAP financial measures; and
- these non-GAAP financial measures were not prepared in
accordance with GAAP or under a comprehensive set of rules or
principles.
Further, these non-GAAP financial measures may be unique to the
Company, as they may be different from similarly titled non-GAAP
financial measures used by other companies. As such, this
presentation of non-GAAP financial measures may not enhance the
comparability of the Company's results to the results of other
companies.
About Axon
Axon is a network of devices, apps and people that helps public
safety personnel become smarter and safer. With a mission of
protecting life, our technologies give customers the confidence,
focus and time they need to keep their communities safe. Our
products impact every aspect of a public safety officer's
day-to-day experience.
We work hard for those who put themselves in harm's way for all
of us. More than 225,000 lives and countless dollars have been
saved with the Axon network of devices, apps and people. Learn more
at www.axon.com or by calling (800) 978-2737. Facebook is a
trademark of Facebook, Inc.; LTE is a trademark of the European
Telecommunications Standards Institute; Oculus is a trademark of
Facebook Technologies, LLC; Twitter is a trademark of Twitter, Inc.
and Zoom is a trademark of Zoom Video Communications, Inc.
Axon, Axon Records, Axon Dispatch, Axon Performance, Axon
Standards, Axon Body, Redaction Assistant, Axon Accelerate, Axon
Evidence, Axon Academy, Axon Fleet, TASER, TASER 7 and the Delta
Logo are trademarks of Axon Enterprise, Inc., some of which are
registered in the US and other countries. For more information,
visit www.axon.com/legal. All rights reserved.
Follow Axon here:
- Axon on Twitter: https://twitter.com/axon_us
- Axon on Facebook:
https://www.facebook.com/Axon.ProtectLife/
Forward-looking statements
These forward-looking statements include, without limitation,
statements regarding: proposed products and services and related
development efforts and activities; expectations about the market
for our current and future products and services; expectations
about customer behavior; statements concerning projections,
predictions, expectations, estimates or forecasts as to our
business, financial and operational results and future economic
performance; and statements of management's strategies, goals and
objectives and other similar expressions; as well as the ultimate
resolution of financial statement items requiring critical
accounting estimates, including those set forth in our Form 10-K
for the year ended December 31, 2019.
Such statements give our current expectations or forecasts of
future events; they do not relate strictly to historical or current
facts. Words such as "may," "will," "should," "could," "would,"
"predict," "potential," "continue," "expect," "anticipate,"
"future," "intend," "plan," "believe," "estimate," and similar
expressions, as well as statements in future tense, identify
forward-looking statements. However, not all forward-looking
statements contain these identifying words.
We cannot guarantee that any forward-looking statement will be
realized, although we believe we have been prudent in our plans and
assumptions. Achievement of future results is subject to risks,
uncertainties and potentially inaccurate assumptions. The following
important factors could cause actual results to differ materially
from those in the forward-looking statements: our ability to
design, introduce and sell new products or features; our ability to
defend against litigation and protect our intellectual property,
and the resulting costs of this activity; our ability to manage our
supply chain and avoid production delays, shortages, and impacts to
expected gross margins; the impact of stock compensation expense,
impairment expense, and income tax expense on our financial
results; customer purchase behavior, including adoption of our
software as a service delivery model; our exposure to cancellations
of government contracts due to appropriation clauses, exercise of a
cancellation clause, or non-exercise of contractually optional
periods; negative media publicity regarding our products; the
impact of product mix on projected gross margins; defects in our
products; changes in the costs of product components and labor;
loss of customer data, a breach of security, or an extended outage,
including our reliance on third party cloud-based storage
providers; exposure to international operational risks; delayed
cash collections and possible credit losses due to our subscription
model; changes in government regulations in the U.S. and in foreign
markets, especially related to the classification of our product by
the United States Bureau of Alcohol, Tobacco, Firearms and
Explosives and to evolving regulations surrounding privacy and data
protection; our ability to integrate acquired businesses; our
ability to attract and retain key personnel; and counter-party
risks relating to cash balances held in excess of FDIC insurance
limits. Many events beyond our control may determine whether
results we anticipate will be achieved. Should known or unknown
risks or uncertainties materialize, or should underlying
assumptions prove inaccurate, actual results could differ
materially from past results and those anticipated, estimated or
projected. You should bear this in mind as you consider
forward-looking statements. Our Annual Report on Form 10-K lists
various important factors that could cause actual results to differ
materially from expected and historical results. These factors are
intended as cautionary statements for investors within the meaning
of Section 21E of the Exchange Act and Section 27A of the
Securities Act. Readers can find them under the heading "Risk
Factors" in the Annual Report on Form 10-K and in the Quarterly
Report on Form 10-Q, and investors should refer to them. You should
understand that it is not possible to predict or identify all such
factors. Consequently, you should not consider any such list to be
a complete set of all potential risks or uncertainties.
Except as required by law, we undertake no obligation to
publicly update forward-looking statements, whether as a result of
new information, future events or otherwise. You are advised,
however, to consult any further disclosures we make on related
subjects in our Form 10-Q, 8-K and 10-K reports to the SEC.
Please visit https://investor.axon.com,
https://www.axon.com/press, www.twitter.com/axon_us and
https://www.facebook.com/Axon.ProtectLife/ where Axon discloses
information about the company, its financial information, and its
business.
For investor relations information please contact Andrea James via email at IR@axon.com.
AXON ENTERPRISE,
INC.
|
CONSOLIDATED
STATEMENTS OF OPERATIONS
|
(Unaudited)
|
(in thousands,
except per share data)
|
|
|
|
|
|
THREE MONTHS
ENDED
|
|
TWELVE MONTHS
ENDED
|
|
|
|
|
|
31 DEC
2019
|
|
30 SEP
2019
|
|
31 DEC
2018
|
|
31 DEC
2019
|
|
31 DEC
2018
|
Net sales from
products
|
$
|
134,497
|
|
|
$
|
96,497
|
|
|
$
|
89,017
|
|
|
$
|
399,474
|
|
|
$
|
327,635
|
|
Net sales from
services
|
37,354
|
|
|
34,340
|
|
|
25,774
|
|
|
131,386
|
|
|
92,433
|
|
Net sales
|
171,851
|
|
|
130,837
|
|
|
114,791
|
|
|
530,860
|
|
|
420,068
|
|
Cost of product
sales
|
70,418
|
|
|
42,445
|
|
|
42,863
|
|
|
190,683
|
|
|
139,337
|
|
Cost of service
sales
|
8,793
|
|
|
8,223
|
|
|
6,582
|
|
|
32,891
|
|
|
22,148
|
|
Cost of
sales
|
79,211
|
|
|
50,668
|
|
|
49,445
|
|
|
223,574
|
|
|
161,485
|
|
Gross
margin
|
92,640
|
|
|
80,169
|
|
|
65,346
|
|
|
307,286
|
|
|
258,583
|
|
Operating
expenses:
|
|
|
|
|
|
|
|
|
|
Sales, general and
administrative
|
78,281
|
|
|
48,424
|
|
|
42,099
|
|
|
212,959
|
|
|
156,886
|
|
Research and
development
|
28,745
|
|
|
25,129
|
|
|
21,254
|
|
|
100,721
|
|
|
76,856
|
|
Total operating
expenses
|
107,026
|
|
|
73,553
|
|
|
63,353
|
|
|
313,680
|
|
|
233,742
|
|
Income (loss) from
operations
|
(14,386)
|
|
|
6,616
|
|
|
1,993
|
|
|
(6,394)
|
|
|
24,841
|
|
Interest and other
income, net
|
2,486
|
|
|
1,820
|
|
|
1,021
|
|
|
8,464
|
|
|
3,263
|
|
Income (loss) before
provision for income taxes
|
(11,900)
|
|
|
8,436
|
|
|
3,014
|
|
|
2,070
|
|
|
28,104
|
|
Provision for
(benefit from) income taxes
|
479
|
|
|
2,332
|
|
|
931
|
|
|
1,188
|
|
|
(1,101)
|
|
Net income
(loss)
|
$
|
(12,379)
|
|
|
$
|
6,104
|
|
|
$
|
2,083
|
|
|
$
|
882
|
|
|
$
|
29,205
|
|
Net income (loss) per
common and common equivalent shares:
|
|
|
|
|
|
|
|
|
|
Basic
|
$
|
(0.21)
|
|
|
$
|
0.10
|
|
|
$
|
0.04
|
|
|
$
|
0.01
|
|
|
$
|
0.52
|
|
Diluted
|
$
|
(0.21)
|
|
|
$
|
0.10
|
|
|
$
|
0.03
|
|
|
$
|
0.01
|
|
|
$
|
0.50
|
|
Weighted average
number of common and common equivalent shares
outstanding:
|
|
|
|
|
|
|
|
|
|
Basic
|
59,374
|
|
|
59,278
|
|
|
58,502
|
|
|
59,190
|
|
|
56,392
|
|
Diluted
|
60,257
|
|
|
60,059
|
|
|
59,665
|
|
|
60,018
|
|
|
57,922
|
|
AXON ENTERPRISE,
INC.
|
SEGMENT
REPORTING
|
(Unaudited)
|
(dollars in
thousands)
|
|
|
|
|
|
|
|
THREE MONTHS
ENDED
31 DEC
2019
|
|
THREE MONTHS
ENDED
30 SEP
2019
|
|
THREE MONTHS
ENDED
31 DEC
2018
|
|
TASER
|
|
Software
and
Sensors
|
|
Total
|
|
TASER
|
|
Software
and
Sensors
|
|
Total
|
|
TASER
|
|
Software
and
Sensors
|
|
Total
|
Net sales from
products (1)
|
$
|
83,406
|
|
|
$
|
51,091
|
|
|
$
|
134,497
|
|
|
$
|
71,424
|
|
|
$
|
25,073
|
|
|
$
|
96,497
|
|
|
$
|
65,301
|
|
|
$
|
23,716
|
|
|
$
|
89,017
|
|
Net sales from
services (2)
|
549
|
|
|
36,805
|
|
|
37,354
|
|
|
319
|
|
|
34,021
|
|
|
34,340
|
|
|
—
|
|
|
25,774
|
|
|
25,774
|
|
Net sales
|
83,955
|
|
|
87,896
|
|
|
171,851
|
|
|
71,743
|
|
|
59,094
|
|
|
130,837
|
|
|
65,301
|
|
|
49,490
|
|
|
114,791
|
|
Cost of product
sales
|
33,144
|
|
|
37,274
|
|
|
70,418
|
|
|
26,504
|
|
|
15,941
|
|
|
42,445
|
|
|
22,874
|
|
|
19,989
|
|
|
42,863
|
|
Cost of service
sales
|
—
|
|
|
8,793
|
|
|
8,793
|
|
|
—
|
|
|
8,223
|
|
|
8,223
|
|
|
—
|
|
|
6,582
|
|
|
6,582
|
|
Cost of
sales
|
33,144
|
|
|
46,067
|
|
|
79,211
|
|
|
26,504
|
|
|
24,164
|
|
|
50,668
|
|
|
22,874
|
|
|
26,571
|
|
|
49,445
|
|
Gross
margin
|
50,811
|
|
|
41,829
|
|
|
92,640
|
|
|
45,239
|
|
|
34,930
|
|
|
80,169
|
|
|
42,427
|
|
|
22,919
|
|
|
65,346
|
|
Gross margin
%
|
60.5
|
%
|
|
47.6
|
%
|
|
53.9
|
%
|
|
63.1
|
%
|
|
59.1
|
%
|
|
61.3
|
%
|
|
65.0
|
%
|
|
46.3
|
%
|
|
56.9
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and
development
|
4,185
|
|
|
24,560
|
|
|
28,745
|
|
|
3,485
|
|
|
21,644
|
|
|
25,129
|
|
|
5,196
|
|
|
16,058
|
|
|
21,254
|
|
|
TWELVE MONTHS
ENDED
31 DEC
2019
|
|
TWELVE MONTHS
ENDED
31 DEC
2018
|
|
TASER
|
|
Software and
Sensors
|
|
Total
|
|
TASER
|
|
Software and
Sensors
|
|
Total
|
Net sales from
products (1)
|
$
|
280,554
|
|
|
$
|
118,920
|
|
|
$
|
399,474
|
|
|
$
|
253,115
|
|
|
$
|
74,520
|
|
|
$
|
327,635
|
|
Net sales from
services (2)
|
1,107
|
|
|
130,279
|
|
|
131,386
|
|
|
—
|
|
|
92,433
|
|
|
92,433
|
|
Net sales
|
281,661
|
|
|
249,199
|
|
|
530,860
|
|
|
253,115
|
|
|
166,953
|
|
|
420,068
|
|
Cost of product
sales
|
107,188
|
|
|
83,495
|
|
|
190,683
|
|
|
80,354
|
|
|
58,983
|
|
|
139,337
|
|
Cost of service
sales
|
—
|
|
|
32,891
|
|
|
32,891
|
|
|
—
|
|
|
22,148
|
|
|
22,148
|
|
Cost of
sales
|
107,188
|
|
|
116,386
|
|
|
223,574
|
|
|
80,354
|
|
|
81,131
|
|
|
161,485
|
|
Gross
margin
|
174,473
|
|
|
132,813
|
|
|
307,286
|
|
|
172,761
|
|
|
85,822
|
|
|
258,583
|
|
Gross margin
%
|
61.9
|
%
|
|
53.3
|
%
|
|
57.9
|
%
|
|
68.3
|
%
|
|
51.4
|
%
|
|
61.5
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and
development
|
14,469
|
|
|
86,252
|
|
|
100,721
|
|
|
17,012
|
|
|
59,844
|
|
|
76,856
|
|
|
(1) Software and Sensors "products"
revenue consists of sensors, including on-officer body cameras,
Axon Fleet cameras, other hardware sensors, warranties on sensors,
and other products, and is sometimes referred to as Sensors and
Other revenue.
|
|
(2)
Software and Sensors "services" revenue comprises sales related to
the Axon Cloud, which includes Axon Evidence, cloud-based evidence
management software revenue, other recurring cloud-hosted software
revenue and related professional services, and is sometimes
referred to as Axon Cloud revenue.
|
AXON ENTERPRISE,
INC.
|
UNIT SALES
STATISTICS
|
(Unaudited)
|
Units in whole
numbers
|
|
|
|
|
|
THREE MONTHS
ENDED
|
|
TWELVE MONTHS
ENDED 31 DEC
|
|
31 DEC
2019
|
|
31 DEC
2018
|
|
Unit
Change
|
|
Percent
Change
|
|
31 DEC
2019
|
|
31 DEC
2018
|
|
Unit
Change
|
|
Percent
Change
|
TASER 7
|
14,577
|
|
|
5,759
|
|
|
8,818
|
|
|
153.1
|
%
|
|
49,221
|
|
|
5,759
|
|
|
43,462
|
|
|
754.7
|
%
|
TASER X26P
|
13,554
|
|
|
18,597
|
|
|
(5,043)
|
|
|
(27.1)
|
|
|
48,798
|
|
|
71,823
|
|
|
(23,025)
|
|
|
(32.1)
|
|
TASER X2
|
11,534
|
|
|
13,088
|
|
|
(1,554)
|
|
|
(11.9)
|
|
|
40,973
|
|
|
65,855
|
|
|
(24,882)
|
|
|
(37.8)
|
|
TASER Pulse and
Bolt
|
2,978
|
|
|
7,490
|
|
|
(4,512)
|
|
|
(60.2)
|
|
|
11,785
|
|
|
18,398
|
|
|
(6,613)
|
|
|
(35.9)
|
|
Cartridges
|
962,519
|
|
|
600,690
|
|
|
361,829
|
|
|
60.2
|
|
|
2,751,603
|
|
|
2,342,897
|
|
|
408,706
|
|
|
17.4
|
|
Axon Body
|
83,268
|
|
|
26,167
|
|
|
57,101
|
|
|
218.2
|
|
|
151,499
|
|
|
85,965
|
|
|
65,534
|
|
|
76.2
|
|
Axon Flex
|
3,078
|
|
|
5,080
|
|
|
(2,002)
|
|
|
(39.4)
|
|
|
15,586
|
|
|
15,541
|
|
|
45
|
|
|
0.3
|
|
Axon Fleet
|
3,324
|
|
|
3,908
|
|
|
(584)
|
|
|
(14.9)
|
|
|
10,467
|
|
|
9,445
|
|
|
1,022
|
|
|
10.8
|
|
Axon Dock
|
10,149
|
|
|
3,859
|
|
|
6,290
|
|
|
163.0
|
|
|
22,275
|
|
|
17,762
|
|
|
4,513
|
|
|
25.4
|
|
TASER Cam
|
1,177
|
|
|
1,952
|
|
|
(775)
|
|
|
(39.7)
|
|
|
5,533
|
|
|
8,310
|
|
|
(2,777)
|
|
|
(33.4)
|
|
AXON ENTERPRISE,
INC.
|
RECONCILIATION OF
GAAP TO NON-GAAP FINANCIAL MEASURES
|
(Unaudited)
|
Dollars in
thousands
|
|
|
|
|
|
THREE MONTHS
ENDED
|
|
TWELVE MONTHS
ENDED
|
|
|
|
|
|
31 DEC
2019
|
|
30 SEP
2019
|
|
31 DEC
2018
|
|
31 DEC
2019
|
|
31 DEC
2018
|
EBITDA and
Adjusted EBITDA:
|
|
|
|
|
|
|
|
|
|
Net income
(loss)
|
$
|
(12,379)
|
|
|
$
|
6,104
|
|
|
$
|
2,083
|
|
|
$
|
882
|
|
|
$
|
29,205
|
|
Depreciation and
amortization
|
3,165
|
|
|
2,709
|
|
|
2,389
|
|
|
11,361
|
|
|
10,615
|
|
Interest
expense
|
19
|
|
|
4
|
|
|
33
|
|
|
46
|
|
|
86
|
|
Investment interest
income
|
(1,760)
|
|
|
(1,647)
|
|
|
(1,076)
|
|
|
(7,040)
|
|
|
(3,002)
|
|
Provision for
(benefit from) income taxes
|
479
|
|
|
2,332
|
|
|
931
|
|
|
1,188
|
|
|
(1,101)
|
|
EBITDA
|
$
|
(10,476)
|
|
|
$
|
9,502
|
|
|
$
|
4,360
|
|
|
$
|
6,437
|
|
|
$
|
35,803
|
|
|
|
|
|
|
|
|
|
|
|
Adjustments:
|
|
|
|
|
|
|
|
|
|
Stock-based
compensation expense
|
$
|
48,300
|
|
|
$
|
13,663
|
|
|
$
|
6,577
|
|
|
$
|
78,495
|
|
|
$
|
21,879
|
|
Transaction costs and
adjustments related to business acquisition
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
1,382
|
|
Loss on disposal and
abandonment of intangible assets
|
16
|
|
|
33
|
|
|
14
|
|
|
67
|
|
|
2,117
|
|
Loss on disposal and
impairment of property and equipment, net
|
134
|
|
|
845
|
|
|
13
|
|
|
2,542
|
|
|
303
|
|
Costs related to FTC
litigation
|
240
|
|
|
—
|
|
|
—
|
|
|
240
|
|
|
—
|
|
Adjusted
EBITDA
|
$
|
38,214
|
|
|
$
|
24,043
|
|
|
$
|
10,964
|
|
|
$
|
87,781
|
|
|
$
|
61,484
|
|
Net income (loss)
as a percentage of net sales
|
(7.2)
|
%
|
|
4.7
|
%
|
|
1.8
|
%
|
|
0.2
|
%
|
|
7.0
|
%
|
Adjusted EBITDA as
a percentage of net sales
|
22.2
|
%
|
|
18.4
|
%
|
|
9.6
|
%
|
|
16.5
|
%
|
|
14.6
|
%
|
|
|
|
|
|
|
|
|
|
|
Stock-based
compensation expense:
|
|
|
|
|
|
|
|
|
|
Cost of product and
service sales
|
$
|
790
|
|
|
$
|
312
|
|
|
$
|
152
|
|
|
$
|
1,565
|
|
|
$
|
511
|
|
Sales, general and
administrative
|
40,212
|
|
|
9,508
|
|
|
3,927
|
|
|
59,342
|
|
|
12,710
|
|
Research and
development
|
7,298
|
|
|
3,843
|
|
|
2,498
|
|
|
17,588
|
|
|
8,658
|
|
Total
|
$
|
48,300
|
|
|
$
|
13,663
|
|
|
$
|
6,577
|
|
|
$
|
78,495
|
|
|
$
|
21,879
|
|
AXON ENTERPRISE,
INC.
|
RECONCILIATION OF
GAAP TO NON-GAAP FINANCIAL MEASURES - continued
|
(Unaudited)
|
Dollars in
thousands
|
|
|
|
|
|
THREE MONTHS
ENDED
|
|
TWELVE MONTHS
ENDED
|
|
|
|
|
|
31 DEC
2019
|
|
30 SEP
2019
|
|
31 DEC
2018
|
|
31 DEC
2019
|
|
31 DEC
2018
|
Non-GAAP net
income:
|
|
|
|
|
|
|
|
|
|
GAAP net income
(loss)
|
$
|
(12,379)
|
|
|
$
|
6,104
|
|
|
$
|
2,083
|
|
|
$
|
882
|
|
|
$
|
29,205
|
|
Non-GAAP
adjustments:
|
|
|
|
|
|
|
|
|
|
Stock-based
compensation expense
|
48,300
|
|
|
13,663
|
|
|
6,577
|
|
|
78,495
|
|
|
21,879
|
|
Loss on disposal and
abandonment of intangible assets
|
16
|
|
|
33
|
|
|
14
|
|
|
67
|
|
|
2,117
|
|
Loss on disposal and
impairment of property and equipment, net
|
134
|
|
|
845
|
|
|
13
|
|
|
2,542
|
|
|
303
|
|
Transaction costs and
adjustments related to business acquisition
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
1,382
|
|
Costs related to FTC
litigation
|
240
|
|
|
—
|
|
|
—
|
|
|
240
|
|
|
—
|
|
Income tax
effects
|
(11,863)
|
|
|
(3,654)
|
|
|
(1,737)
|
|
|
(20,068)
|
|
|
(6,366)
|
|
Income tax benefit of
CEO stock option exercise
|
—
|
|
|
—
|
|
|
(2,321)
|
|
|
—
|
|
|
(5,683)
|
|
Non-GAAP net
income
|
$
|
24,448
|
|
|
$
|
16,991
|
|
|
$
|
4,629
|
|
|
$
|
62,158
|
|
|
$
|
42,837
|
|
|
|
|
|
|
THREE MONTHS
ENDED
|
|
TWELVE MONTHS
ENDED
|
|
|
|
|
|
31 DEC
2019
|
|
30 SEP
2019
|
|
31 DEC
2018
|
|
31 DEC
2019
|
|
31 DEC
2018
|
Non-GAAP diluted
earnings per share:
|
|
|
|
|
|
|
|
|
|
GAAP diluted earnings
per share
|
$
|
(0.21)
|
|
|
$
|
0.10
|
|
|
$
|
0.03
|
|
|
$
|
0.01
|
|
|
$
|
0.50
|
|
Non-GAAP
adjustments:
|
|
|
|
|
|
|
|
|
|
Stock-based
compensation expense
|
0.80
|
|
|
0.23
|
|
|
0.11
|
|
|
1.31
|
|
|
0.38
|
|
Loss on disposal and
abandonment of intangible assets
|
0.00
|
|
|
0.00
|
|
|
0.00
|
|
|
0.00
|
|
|
0.04
|
|
Loss on disposal and
impairment of property and equipment, net
|
0.00
|
|
|
0.01
|
|
|
0.00
|
|
|
0.04
|
|
|
0.01
|
|
Transaction costs and
adjustments related to business acquisition
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
0.02
|
|
Costs related to FTC
litigation
|
0.00
|
|
|
—
|
|
|
—
|
|
|
0.00
|
|
|
—
|
|
Income tax
effects
|
(0.20)
|
|
|
(0.06)
|
|
|
(0.03)
|
|
|
(0.33)
|
|
|
(0.11)
|
|
Income tax benefit of
CEO stock option exercise
|
—
|
|
|
—
|
|
|
(0.04)
|
|
|
—
|
|
|
(0.10)
|
|
Non-GAAP diluted
earnings per share (1)
|
$
|
0.41
|
|
|
$
|
0.28
|
|
|
$
|
0.08
|
|
|
$
|
1.04
|
|
|
$
|
0.74
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average
number of diluted common and common equivalent shares outstanding
(in thousands)
|
60,257
|
|
|
60,059
|
|
|
59,665
|
|
|
60,018
|
|
|
57,922
|
|
|
(1) The per share calculations for
GAAP net income, Non-GAAP adjustments and Non-GAAP diluted earnings
per share are each computed independently. Per share amounts may
not sum due to rounding.
|
AXON ENTERPRISE,
INC.
|
CONSOLIDATED
BALANCE SHEETS
|
(in
thousands)
|
|
|
|
|
|
31 DEC
2019
|
|
31 DEC
2018
|
|
(Unaudited)
|
|
|
ASSETS
|
Current
Assets:
|
|
|
|
Cash and cash
equivalents
|
$
|
172,250
|
|
|
$
|
349,462
|
|
Short-term
investments
|
178,534
|
|
|
—
|
|
Accounts and notes
receivable, net
|
146,878
|
|
|
130,579
|
|
Contract assets,
net
|
47,718
|
|
|
13,960
|
|
Inventory,
net
|
38,845
|
|
|
33,763
|
|
Prepaid expenses and
other current assets
|
34,866
|
|
|
30,391
|
|
Total current
assets
|
619,091
|
|
|
558,155
|
|
|
|
|
|
Property and
equipment, net
|
43,770
|
|
|
37,893
|
|
Deferred tax assets,
net
|
27,688
|
|
|
19,347
|
|
Intangible assets,
net
|
12,771
|
|
|
15,935
|
|
Goodwill
|
25,013
|
|
|
24,981
|
|
Long-term
investments
|
45,499
|
|
|
—
|
|
Long-term notes
receivable, net of current portion
|
31,598
|
|
|
40,230
|
|
Other
assets
|
40,209
|
|
|
22,999
|
|
Total
assets
|
$
|
845,639
|
|
|
$
|
719,540
|
|
|
LIABILITIES AND
STOCKHOLDERS' EQUITY
|
Current
Liabilities:
|
|
|
|
Accounts
payable
|
25,874
|
|
|
15,164
|
|
Accrued
liabilities
|
45,001
|
|
|
41,092
|
|
Current portion of
deferred revenue
|
117,864
|
|
|
107,016
|
|
Customer
deposits
|
2,974
|
|
|
2,702
|
|
Other current
liabilities
|
3,853
|
|
|
37
|
|
Total current
liabilities
|
195,566
|
|
|
166,011
|
|
|
|
|
|
Deferred revenue, net
of current portion
|
87,936
|
|
|
74,417
|
|
Liability for
unrecognized tax benefits
|
3,832
|
|
|
2,849
|
|
Long-term deferred
compensation
|
3,936
|
|
|
3,235
|
|
Deferred tax
liability
|
354
|
|
|
—
|
|
Other long-term
liabilities
|
10,520
|
|
|
5,704
|
|
Total
liabilities
|
302,144
|
|
|
252,216
|
|
|
|
|
|
Stockholders'
Equity:
|
|
|
|
Preferred
stock
|
—
|
|
|
—
|
|
Common
stock
|
1
|
|
|
1
|
|
Additional paid-in
capital
|
528,272
|
|
|
453,400
|
|
Treasury
stock
|
(155,947)
|
|
|
(155,947)
|
|
Retained
earnings
|
172,265
|
|
|
171,383
|
|
Accumulated other
comprehensive loss
|
(1,096)
|
|
|
(1,513)
|
|
Total
stockholders' equity
|
543,495
|
|
|
467,324
|
|
Total liabilities
and stockholders' equity
|
$
|
845,639
|
|
|
$
|
719,540
|
|
AXON ENTERPRISE,
INC.
|
UNAUDITED
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
|
(in
thousands)
|
|
|
|
|
|
THREE MONTHS
ENDED
|
|
TWELVE MONTHS
ENDED
|
|
|
|
|
|
31 DEC
2019
|
|
30 SEP
2019
|
|
31 DEC
2018
|
|
31 DEC
2019
|
|
31 DEC
2018
|
Cash flows from
operating activities:
|
|
|
|
|
|
|
|
|
|
Net income
(loss)
|
$
|
(12,379)
|
|
|
$
|
6,104
|
|
|
$
|
2,083
|
|
|
$
|
882
|
|
|
$
|
29,205
|
|
Adjustments to
reconcile net income to net cash provided by operating
activities:
|
|
|
|
|
|
|
|
|
|
Depreciation and
amortization
|
3,165
|
|
|
2,709
|
|
|
2,389
|
|
|
11,361
|
|
|
10,615
|
|
Loss on disposal and
abandonment of intangible assets
|
16
|
|
|
33
|
|
|
14
|
|
|
67
|
|
|
2,117
|
|
Loss (gain) on
disposal and impairment of property and equipment, net
|
134
|
|
|
845
|
|
|
13
|
|
|
2,542
|
|
|
303
|
|
Stock-based
compensation
|
48,300
|
|
|
13,663
|
|
|
6,577
|
|
|
78,495
|
|
|
21,879
|
|
Deferred income
taxes
|
(4,041)
|
|
|
(2,635)
|
|
|
(1,266)
|
|
|
(7,987)
|
|
|
(3,592)
|
|
Unrecognized tax
benefits
|
389
|
|
|
(19)
|
|
|
1,045
|
|
|
983
|
|
|
1,144
|
|
Other noncash,
net
|
1,005
|
|
|
1,101
|
|
|
—
|
|
|
3,928
|
|
|
34
|
|
Change in assets and
liabilities:
|
|
|
|
|
|
|
|
|
|
Accounts and notes
receivable and contract assets
|
(8,333)
|
|
|
(19,491)
|
|
|
(16,471)
|
|
|
(38,830)
|
|
|
(67,643)
|
|
Inventory
|
1,399
|
|
|
1,213
|
|
|
5,771
|
|
|
(4,903)
|
|
|
14,804
|
|
Prepaid expenses and
other assets
|
2,122
|
|
|
(6,206)
|
|
|
(658)
|
|
|
(9,845)
|
|
|
(12,739)
|
|
Accounts payable,
accrued liabilities and other liabilities
|
18,495
|
|
|
3,224
|
|
|
9,200
|
|
|
4,967
|
|
|
13,506
|
|
Deferred
revenue
|
(4,463)
|
|
|
21,899
|
|
|
22,542
|
|
|
24,013
|
|
|
54,242
|
|
Net cash provided by
operating activities
|
45,809
|
|
|
22,440
|
|
|
31,239
|
|
|
65,673
|
|
|
63,875
|
|
Cash flows from
investing activities:
|
|
|
|
|
|
|
|
|
|
Purchases of
investments
|
(111,784)
|
|
|
(100,701)
|
|
|
—
|
|
|
(354,477)
|
|
|
(4,331)
|
|
Proceeds from call /
maturity of investments
|
37,876
|
|
|
66,888
|
|
|
500
|
|
|
130,083
|
|
|
11,158
|
|
Purchases of property
and equipment
|
(3,828)
|
|
|
(4,250)
|
|
|
(4,259)
|
|
|
(15,939)
|
|
|
(11,139)
|
|
Purchases of
intangible assets
|
(76)
|
|
|
16
|
|
|
(98)
|
|
|
(404)
|
|
|
(558)
|
|
Business
acquisitions, net of cash acquired
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(4,990)
|
|
Net cash used in
investing activities
|
(77,812)
|
|
|
(38,047)
|
|
|
(3,857)
|
|
|
(240,737)
|
|
|
(9,860)
|
|
Cash flows from
financing activities:
|
|
|
|
|
|
|
|
|
|
Net proceeds from
equity offering
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
233,993
|
|
Proceeds from options
exercised
|
8
|
|
|
2
|
|
|
1,044
|
|
|
114
|
|
|
1,757
|
|
Income and payroll
tax payments for net-settled stock awards
|
(783)
|
|
|
(1,136)
|
|
|
(2,154)
|
|
|
(4,051)
|
|
|
(14,127)
|
|
Payment of contingent
consideration for business acquisitions
|
—
|
|
|
—
|
|
|
(1,700)
|
|
|
—
|
|
|
(2,275)
|
|
Net cash provided by
(used in) financing activities
|
(775)
|
|
|
(1,134)
|
|
|
(2,810)
|
|
|
(3,937)
|
|
|
219,348
|
|
Effect of exchange
rate changes on cash and cash equivalents
|
1,007
|
|
|
(426)
|
|
|
(393)
|
|
|
329
|
|
|
(774)
|
|
Net increase
(decrease) in cash and cash equivalents and restricted
cash
|
(31,771)
|
|
|
(17,167)
|
|
|
24,179
|
|
|
(178,672)
|
|
|
272,589
|
|
Cash and cash
equivalents, beginning of period
|
204,126
|
|
|
221,293
|
|
|
326,848
|
|
|
351,027
|
|
|
78,438
|
|
Cash and cash
equivalents, end of period
|
$
|
172,355
|
|
|
$
|
204,126
|
|
|
$
|
351,027
|
|
|
$
|
172,355
|
|
|
$
|
351,027
|
|
AXON ENTERPRISE,
INC.
|
SELECTED CASH FLOW
INFORMATION
|
(Unaudited)
|
(in
thousands)
|
|
|
|
|
|
THREE MONTHS
ENDED
|
|
TWELVE MONTHS
ENDED
|
|
|
|
|
|
31 DEC
2019
|
|
30 SEP
2019
|
|
31 DEC
2018
|
|
31 DEC
2019
|
|
31 DEC
2018
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by
operating activities
|
$
|
45,809
|
|
|
$
|
22,440
|
|
|
$
|
31,239
|
|
|
$
|
65,673
|
|
|
$
|
63,875
|
|
Purchases of property
and equipment
|
(3,828)
|
|
|
(4,250)
|
|
|
(4,259)
|
|
|
(15,939)
|
|
|
(11,139)
|
|
Purchases of
intangible assets
|
(76)
|
|
|
16
|
|
|
(98)
|
|
|
(404)
|
|
|
(558)
|
|
Cash flows related to
business acquisitions
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(4,990)
|
|
Free cash flow, a
non-GAAP measure
|
$
|
41,905
|
|
|
$
|
18,206
|
|
|
$
|
26,882
|
|
|
$
|
49,330
|
|
|
$
|
47,188
|
|
AXON ENTERPRISE,
INC.
|
SUPPLEMENTAL
TABLES
|
(in
thousands)
|
|
|
|
|
|
31 DEC
2019
|
|
31 DEC
2018
|
|
(Unaudited)
|
|
|
|
|
|
|
Cash and cash
equivalents
|
$
|
172,250
|
|
|
$
|
349,462
|
|
Short-term
investments
|
178,534
|
|
|
—
|
|
Long-term
investments
|
45,499
|
|
|
—
|
|
Total cash and cash
equivalents and investments
|
$
|
396,283
|
|
|
$
|
349,462
|
|
CONTACT:
Investor Relations
Axon Enterprise, Inc.
IR@axon.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/axon-2019-revenue-grows-26-to-531-million-saas-arr-up-49-setting-foundation-for-continued-growth--momentum-301012955.html
SOURCE Axon